Fusion Antibodies PLC
LSE:FAB
Intrinsic Value
The intrinsic value of one
FAB
stock under the Base Case scenario is
57.39
GBX.
Compared to the current market price of 31.5 GBX,
Fusion Antibodies PLC
is
Undervalued by 45%.
The Intrinsic Value is calculated as the average of the two valuation methods:
Fundamental Analysis
FAB Profitability Score
Profitability Due Diligence
Fusion Antibodies PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Fusion Antibodies PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
FAB Solvency Score
Solvency Due Diligence
Fusion Antibodies PLC's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Score
Fusion Antibodies PLC's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
Fusion Antibodies PLC
| Current Assets | 3.2M |
| Cash & Short-Term Investments | 1.2M |
| Receivables | 1.5M |
| Other Current Assets | 552k |
| Non-Current Assets | 743k |
| PP&E | 743k |
| Current Liabilities | 1.1M |
| Accounts Payable | 1.1M |
| Other Current Liabilities | 83k |
| Non-Current Liabilities | 270k |
| Long-Term Debt | 250k |
| Other Non-Current Liabilities | 20k |
FAB Capital Structure
Fusion Antibodies PLC
| Market Capitalization | 8.2M GBX | |
| Total Debt | 250k GBX | |
| Minority Interest | 0 GBX | |
| Preferred Equity | 0 GBX | |
| Cash and Equivalents | 1.2M GBX | |
| Short-Term Investments | 0 GBX | |
| Enterprise Value | 7.2M GBX | |
Wall St
Price Targets
FAB Price Targets Summary
Fusion Antibodies PLC
Shareholder Return
FAB Return Decomposition
Main factors of price return
is not available
It is impossible to break down the market cap return as the net margin from 5 years ago is negative.
FAB Price
Fusion Antibodies PLC
| Average Annual Return | 9.27% |
| Standard Deviation of Annual Returns | 51.5% |
| Max Drawdown | -85% |
| Market Capitalization | 8.2M GBX |
| Shares Outstanding | 26 014 946 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Fusion Antibodies PLC
Country
Industry
Market Cap
Dividend Yield
Description
Fusion Antibodies Plc engages in the provision of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company is headquartered in Belfast, Northern Ireland and currently employs 54 full-time employees. The company went IPO on 2017-12-18. The firm offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The principal activity of the Company is the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The Company’s services include discovery, engineering and supply. Discovery services includes creation, screening and sequencing of monoclonal antibodies for therapeutic and diagnostic applications. Engineering services includes maximizing the performance of an antibody drug including CDRx humanization, Antibody Developability by Design (ADDTM) and RAMP. Supply services includes the production of material for clinical production or further research, including cGMP ready stable cell line development and transient expression.
Contact
IPO
Employees
Officers
The intrinsic value of one
FAB
stock under the Base Case scenario is
57.39
GBX.
Compared to the current market price of 31.5 GBX,
Fusion Antibodies PLC
is
Undervalued by 45%.
